Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Deadly viruses could become endemic in Europe unless urgent measures are taken, a leading expert has warned. Rising global ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

Symptoms of the flu can include high fever, muscle aches, body pain and headache. But if you’re seeing red flag symptoms like ...

Some people may not develop any symptoms after contracting HIV and could remain undiagnosed until the symptoms of AIDS appear. This could be up to 10 years later. However, 50% or more of people living ...